P21 vs Pinealon
A side-by-side research comparison of P21 and Pinealon across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | P21 | Pinealon |
|---|---|---|
| Full name | P21 (CNTF-Derived Tetrapeptide) | Pinealon (Glu-Asp-Arg) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Research compound | Research compound |
| Mechanism | Mimics CNTF neurogenesis-enhancing portion by increasing BDNF and activating PI3K/Akt. Inhibits LIF signaling to selectively promote neural stem cell proliferation. | As a peptide bioregulator it is proposed to penetrate cells and interact with DNA to modulate gene expression in neural tissue, reducing oxidative damage and supporting neuronal survival and protein synthesis. |
| Molecular weight | ~450 Da | ~418 Da |
| Half-life | 4-6 hours | Short (small peptide, rapidly metabolized) |
| Bioavailability | Moderate (crosses BBB) | Injectable in research; intranasal also used |
| Typical dose | 50-100 mcg/kg | ~5-10 mg per course day (research) |
| Frequency | Daily | Daily during a short course |
| Route | Intranasal or Subcutaneous | Subcutaneous or intranasal |
P21 reported benefits
- Hippocampal neurogenesis
- BDNF increase
- Cognitive enhancement
- BBB penetrant
- No appetite suppression
- Dendritic branching
Pinealon reported benefits
- Neuroprotective and antioxidant effects (research)
- Supports cognition under stress/aging
- May support healthy sleep-wake regulation
- Short-course bioregulator profile
Related comparisons
Research and educational reference only. Not medical advice.